HighlightsSQM reported total revenues for the twelve months ended December 31, 2025 of US$4,576.2 million compared to total revenues of US$4,528.8 million for the same period last year.Net income for the twelve months ended December 31, 2025 of US$588.1 million or US$2.06 per share, compared to net loss of US$(404.4) million or US$(1.42) per share for the same period last year.In lithium: Record quarterly sales volumes amidst strong market demandStrong price environment in iodine SQM will hold a conference call to discuss these results on Monday, March 2, 2026 at 10:00am EST (12:00pm Chile time).Participant Call link:https://register-conf.media-server.com/register/BI256bddfcaae643f591a9cfc6b2a449d6Webcast:https://edge.media-server.com/mmc/p/f6nxktxeSANTIAGO, Chile, Feb. 27, 2026 (GLOBE NEWSWIRE)...

~ $2.5 Billion in Financial Assets ~~ Positive Operating Cash Flow for 2025 ~~ $44 Million in Cash Proceeds from Options Strategy ~ SARASOTA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) — Trump Media and Technology Group Corp. (Nasdaq: DJT) (“TMTG” or the “Company”), operator of the social media platform Truth Social, the video streaming service Truth+, and the financial services and FinTech brand Truth.Fi, announced its financial results for the full year ending on December 31, 2025. These results are included in TMTG’s Annual Report on Form 10-K that will be filed with the Securities and Exchange Commission (the “SEC”) today. TMTG closed 2025 with financial assets of approximately $2.5 billion comprising cash, restricted cash, short-term investments, equity securities, note receivable, digital...

HOUSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) — Chart Industries, Inc. (NYSE: GTLS) today reported results for the fourth quarter and full year ended December 31, 2025. Full year 2025 compared to full year 2024:Orders of $5.68 billion increased 13.4%; full year 2025 book-to-bill of 1.33 Sales of $4.26 billion increased 2.5%; sales increased 4.1% excluding a large lifecycle project and a large aftermarket equipment sale in 2024, which did not repeat in 2025 Reported operating income of $358.4 million (8.4% of sales) or $884.4 million when adjusted for deal related costs and step-up amortization related to the Howden acquisition, resulted in 20.7% adjusted operating income margin, a decrease of 40 bps; adjusted operating income increased 6.2% and adjusted operating income margin increased 50bps excluding a large lifecycle project and...

LAGUNA HILLS, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) — Elite Express Holding Inc. (“ETS” or the “Company”) (Nasdaq CM: ETS), a California-based provider of last-mile delivery services, today reported results for the financial year ended November 30, 2025 and provided a corporate update. For the year ended November 30, 2025, the Company reported revenue of approximately $2.7 million, representing a 9.1% increase compared with the same period in 2024. The Company reported a net loss of approximately $2.2 million compared with a net loss of approximately $0.4 million in 2024. Yidan Chen, ETS’s CEO commented, “Fiscal year 2025 represents a transformational year for ETS, marked by our successful transition to a publicly listed company on August 20, 2025. For the full year, we generated revenue of $2.7 million and achieved remained modestly...

MANAGEMENT COMMENTARYPRFoods’ second quarter of the financial year continued to take place in a challenging economic environment, characterized by weak consumption, price sensitivity, and increased cost pressure. This has particularly affected the Group’s operations in Estonia and nearby markets. At the same time, management has remained focused on core activities, cost control, and strengthening the financial structure. In the second quarter of the financial year, the Group’s revenue amounted to EUR 5.1 million, decreasing by EUR 1.7 million, or 25%, compared to the same period last year. The decline in revenue was mainly due to lower sales volumes in the Estonian and Finnish markets. Quarterly gross profit was EUR 1.0 million, down 43% year-on-year, reflecting lower production volumes and price pressure. EBITDA in the second quarter...

MANAGEMENT REPORT Nordic Fibreboard AS consolidated net revenue in Q4 2025 was €1.74 million, representing a 14.7% increase compared to the same period of the previous year (Q4 2024: €1.51 million). The Group’s main business activity is the production and wholesale of fibreboard, which accounted for the vast majority of the Group’s revenue in Q4 2025. The second segment is the management of the property located on Suur-Jõe Street in Pärnu, which contributed 0.04% of total Q4 2025 revenue (Q4 2024: 0.1%). In August 2024, the lease agreements for the building on Suur-Jõe Street were terminated due to the specific characteristics of the production building complex located there, which caused high administrative costs that rental income was unable to cover. Q4 2025 revenue increased by €222 thousand compared to Q4 2024. Revenue...

Strong cash position at year-end 2025: $33.3 million (€28.4 million)CNS(Vafidemstat)Appointed renowned Rolando Gutierrez-Esteinou, M.D. as new CMO for CNS Preparing protocol resubmission to incorporate FDA guidance on Phase III PORTICO-2 trial in aggression in BPD Ongoing expansion of Phase IIb schizophrenia trial into additional EU countries Finalizing preparations for new Phase II trial in aggression in autism spectrum disorder as a part of the IPCEI EU Grant in personalized medicineOncology – Hematology(Iadademstat)Seven ongoing oncology trials, with six sponsored by the NCI or top-tier U.S. institutions Positive data in 1L AML unfit patients presented at ASH with 100% ORR (90% strict CR) Positive data in R/R FLT3+ AML presented at ASH; 67% CCR at the selected dose under expansion Initiated enrollment in new Phase Ib...

Fourth Quarter Highlights:GAAP net income of $0.07 per diluted common share Distributable earnings1 of $0.19, or $0.22 per diluted common share, excluding $5.1 million of net realized losses from the resolution of certain legacy assets previously reserved for Declares cash dividend on common stock of $0.30 per share Agency loan originations of $1.63 billion Structured loan originations of $1.10 billion, our strongest quarter in over three years Issued $400.0 million of 8.50% senior unsecured notes due 2028 Unwound CLO 16 with $482.1 million of outstanding notes generating ~$90 million of liquidity Foreclosed on six loans totaling $139.0 million and sold three real estate owned properties totaling $77.6 million Repurchased $20.0 million of stock at an average price of $7.40 per share, or 64% of book value, between December 2025 and February...

PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026 CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with gemcitabine in high-risk (HR) NMIBC expected first half 2026 Well-positioned to deliver on key milestones with approximately $903.0 million cash, cash equivalents and marketable securities sufficient to fund operations into the first half of 2029IRVINE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the fourth quarter and year ended December 31, 2025, and provided business updates. “In the coming months, we look forward to sharing topline data from PIVOT-006, the first randomized registrational trial to evaluate an investigational therapy in intermediate-risk...

– Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months – – Evorpacept biomarker strategy validated by data from both the Phase 2 ASPEN-06 gastric cancer trial and the Phase 1b/2 breast cancer trial, independently suggesting CD47 overexpression is predictive of evorpacept activity and drives durable benefit in HER2-positive cancers – – Full biomarker analysis from Phase 1b/2 evorpacept-zanidatamab combination trial accepted for poster presentation at ESMO Breast Cancer 2026 Annual Congress – – Phase 2 ASPEN-09 breast cancer trial is currently enrolling patients and will evaluate...